Oxford Biomedica PLC is a United Kingdom-based biopharmaceutical company. The Company is engaged in advanced therapy medicinal products. The Company designs, develops and manufactures gene-based medicines and therapeutic vaccines. The Company's technology platform includes LentiVector gene delivery technology, which has specific advantages for targeting diseases of the eye and central nervous system and a tumour antigen (5T4), which is a target for anti-cancer therapy. Its product pipeline addresses diseases, including ocular diseases, neurodegenerative disorders and cancer.